Business Wire - July 21, 2000
A total of 200 patients with AIDS-related Kaposi's sarcoma are needed to participate in a multi-national Phase III randomized, placebo-controlled, double-blinded study of IM862 (developed by Cytran, Inc. of Kirkland, WA). This study is assessing the safety and efficacy of IM862 and is conducted in collaboration with the AIDS Malignancy Consortium of the National Cancer Institute. U.S. clinical trial sites can be found in: New York, Los Angeles, San Francisco, Seattle, San Diego, Chicago, Boston, Miami, Cleveland, Baltimore, Columbus, Philadelphia, St. Louis, Nashville and Newark. International cities include: Toronto, Vancouver, Montreal, Ottawa, Brussels, Melbourne, and Sydney.
Preclinical research suggests that IM862's anti-cancer properties include inhibition of blood vessel growth (angiogenesis) and stimulation of the immune system. Patients in the trial will be randomized to receive either IM862 or placebo and will self-administer treatments by placing a few drops of IM862 solution or placebo into the nose every other day. Patients will be seen every four weeks for evaluation of response and toxicity. Key patient eligibility criteria include the following: HIV infection, biopsy-proven Kaposi's sarcoma with five or more measurable lesions, patient on stable antiretroviral therapy for at least 8 weeks, and no symptomatic visceral disease. Study duration is six months. Patients on placebo who experience disease progression, or those who have stable disease at the end of the study, will be offered continued IM862 treatment. Patients who have responded to the first six months of treatment may continue on blinded treatment.
Research has shown that tumors rely on the development of new blood vessels to grow, a process called angiogenesis. Anti-angiogenesis drugs halt the growth of new blood vessels, thus starving the tumors. Preclinical data suggest that IM862 has multiple mechanisms of action including angiogenesis inhibition and stimulation of the body's immune system to attack the tumor. The drug is also being tested in other studies in patients with prostate cancer, colorectal cancer, ovarian cancer and malignant melanoma.
Results of a Phase II trial of IM862 in patients with AIDS-related Kaposi's sarcoma were presented at the 1999 Annual Meeting of the American Society of Clinical Oncology (ASCO) and recently published in the February 2000 issue of the Journal of Clinical Oncology. In that study, 37 percent of patients experienced either a complete or partial response and an additional 48 percent did not have their cancer progress. Average onset of response was 6 weeks after beginning therapy. Complete response was defined as biopsy-proven resolution of Kaposi's sarcoma lesions for four weeks or more without evidence of new disease. Partial response was defined as a reduction in the measurements of 5 target lesions by 50 percent or more, or complete flattening of half or more total lesions. Treatment was well tolerated with minimal side effects.
IM862 is a naturally occurring peptide that is manufactured using conventional pharmaceutical peptide technology. IM862 is readily absorbed into the bloodstream when administered as nose drops. Cytran chose KS for IM862's first indication to demonstrate angiogenesis inhibition because of this malignant tumor's highly vascular nature, and because changes in the tumor are easily observed and measured. KS is a cancer associated with HIV.
Information on this study, study sites and enrollment criteria is available at the AIDS Clinical Trials Information Service, www.actis.org, keyword "IM862". ACTIS is sponsored by the U.S. Food & Drug Administration, the National Institute for Allergy & Infectious Disease, the National Library of Medicine, and the Centers for Disease Control and Prevention. The organization can also be called at 800/trials-A.
Cytran, Inc., based near Seattle, is a privately held biopharmaceutical company, developing and commercializing small peptides for the treatment of cancer and other diseases. The Company has an agreement with ALZA Corporation granting marketing rights to IM862 in the United States and Canada.
--30--BP/se*
CONTACT: For Cytran, Inc. The Faros Group Doris Christelis, 978/440-8406
000721
BW000704
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .